Sicker Patients for Liver Transplantation: Meld, Meld Sodium, and Integrated Meld’s Prognostic Accuracy in the Assessment of Posttransplantation Events at a Single Center from Argentina

Table 2

Variables associated with risk of mortality at 3 months following LT. Univariate logistic regression analysis.

Parameters	Survivors; 𝑛=137	Nonsurvivors; 𝑛=15	𝑃 value
Total bilirubin (mg/dL)*	9±9	16±10	0.005
INR*	2.1±0.9	2.7±1.3	0.03
Creatinine (mg/dL)*	1.1±0.7	1.5±0.7	0.07
GFR-MDRD (mL/min)*	75±35	51±25	0.01
Hyponatremia <130 mEq/L (%)*	16.7	26.6	0.34
Hyponatremia <126 mEq/L (%)*	6.5	0	0.31
Hypernatremia >145 mEq/L (%)*	0.7	13.3	0.0009
Total blood products (units)	41±33	83±51	<0.0001
Monoclonal antibodies induction (%)	22.6	46.6	0.02
Mean ICU stay (days)	7	13	0.001
Mean AMV (days)	2	5	0.05
Female gender (%)	37.9	66.6	0.03
RRT after LT	2.2	20	0.0008
Child pugh	10±2	11±1	0.08
MELD	23±7	28±8	0.005
MELD Na1	27±10	33±8	0.03
MELD Na2	25±7	29±5	0.06
iMELD	46±8	51±6	0.01
MELD <20 (%)	36.5	6.6	0.02
MELD >30 (%)	15.3	40	0.01

Note. Normal values: creatinine 0.6–1.1 mg/dL, serum sodium 135–145 mEq/L. ∗Pre-LT variables. Continuous variables are shown as mean ± standard deviation (SD).
AMV: assisted mechanical ventilation; BMI: body mass index; CIT: cold ischemic time; DM: diabetes mellitus before LT; GFR-MDRD: glomerular filtration rate calculated by Modification of Diet in Renal Disease equation; HAT: hepatic artery thrombosis after liver transplantation; MELD: Model for End-Stage Liver Disease: 9.6 × logn (Creat mg/dL) + 3.8 × logn (tot bil mg/dL) + 11.2 × logn (RIN) + 6.4. MELD Na1: MELD sodium 1: MELD + 1.59 × (135-patient's serum sodium mEq/L); MELD Na2: MELD sodium 2: MELD-Na − [0.025 × MELD × (140 − Na)] + 140; iMELD: Integrated MELD: MELD + (age × 0.3) − (0.7 × Na p) + 100; INR: international normalized ratio; WIT: warm ischemic time; RRT: renal replacement therapy; total blood products: total blood products consumption during the first 48 hrs after liver transplantation; monoclonal antibodies induction: use of Basiliximab (20 mg day 0 and 20 mg day 4); PVT: portal vein thrombosis after LT.